-transparent.png){kind=logo}
Of seven cDNA-expressed human cytochrome P450 (P450) enzymes (P450s 1A2, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4) examined, P450 1A2 was the most active in catalyzing 2- and 4-hydroxylations of estradiol and estrone. P450 3A4 and P450 2C9 also catalyzed these reactions although to lesser extents than P450 1A2. P450 1A2 also efficiently oxidized estradiol at the 16alpha-position but was less active in estrone 16alpha-hydroxylation; the latter reaction and also estradiol 16alpha-hydroxylation were catalyzed by P450 3A4 at significant levels. Anti-P450 1A2 antibodies inhibited 2- and 4-hydroxylations of these two estrogens catalyzed by liver microsomes of some of the human samples examined. Estradiol 16alpha-hydroxylation was inhibited by both anti-P450 1A2 and anti-P450 3A4, while estrone 16alpha-hydroxylation was significantly suppressed by anti-P450 3A4 in human liver microsomes. Fluvoxamine efficiently inhibited the estrogen hydroxylations in human liver samples that contained high levels of P450 1A2, while ketoconazole affected these activities in human samples in which P450 3A4 levels were high. alpha-Naphthoflavone either stimulated or had no effect on estradiol hydroxylation catalyzed by liver microsomes; the intensity of this effect depended on the human samples and their P450s. Interestingly, in the presence of anti-P450 3A4 antibodies, alpha-naphthoflavone was found to be able to inhibit estradiol and estrone 2-hydroxylations catalyzed by human liver microsomes. The results suggest that both P450s 1A2 and 3A4 have major roles in oxidations of estradiol and estrone in human liver and that the contents of these two P450 forms in liver microsomes determine which P450 enzymes are most important in hepatic estrogen hydroxylation by individual humans. P450 3A4 may be expected to play a more important role for some of the estrogen hydroxylation reactions than P450 1A2. Knowledge of roles of individual P450s in these estrogen hydroxylations has relevance to current controversies in hormonal carcinogenesis [Service, R. F. (1998) Science 279, 1631-1633].
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
February 2003,
Toxicology letters,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
December 1996,
Toxicology and applied pharmacology,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
July 2018,
Chemical research in toxicology,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
July 2024,
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
January 1997,
Carcinogenesis,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
February 1996,
Biochemical pharmacology,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
October 1997,
Archives of biochemistry and biophysics,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
November 2000,
Drug metabolism and disposition: the biological fate of chemicals,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
June 2001,
The Journal of pharmacy and pharmacology,
H Yamazaki, and
P M Shaw, and
F P Guengerich, and
T Shimada
August 2012,
The Journal of biological chemistry,
